TISIDB

Summary
Symbol	MICAL3
Name	microtubule associated monooxygenase, calponin and LIM domain containing 3
Aliases	KIAA0819; MICAL-3; flavoprotein oxidoreductase MICAL3; molecule interacting with CasL protein 3; protein MIC ......
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Cytoplasm, cell cortex Cytoplasm, cytoskeleton Nucleus Midbody Cytoplasm, cytoskeleton, spindle Cytoplasm, cytoskeleton, cilium basal body Note=Mainly localizes in the nucleus.
Domain	PF00307 Calponin homology (CH) domain PF12130 Protein of unknown function (DUF3585) PF01494 FAD binding domain PF00412 LIM domain
Function	Monooxygenase that promotes depolymerization of F-actin by mediating oxidation of specific methionine residues on actin to form methionine-sulfoxide, resulting in actin filament disassembly and preventing repolymerization. In the absence of actin, it also functions as a NADPH oxidase producing H(2)O(2). Seems to act as Rab effector protein and plays a role in vesicle trafficking. Involved in exocytic vesicles tethering and fusion: the monooxygenase activity is required for this process and implicates RAB8A associated with exocytotic vesicles. Required for cytokinesis. Contributes to stabilization and/or maturation of the intercellular bridge independently of its monooxygenase activity. Promotes recruitment of Rab8 and ERC1 to the intercellular bridge, and together these proteins are proposed to function in timely abscission.

> Gene Ontology [ TOP ]
Biological Process	GO:0006887 exocytosis GO:0007015 actin filament organization GO:0008154 actin polymerization or depolymerization GO:0030042 actin filament depolymerization GO:0032984 macromolecular complex disassembly GO:0043241 protein complex disassembly GO:0043624 cellular protein complex disassembly GO:0051261 protein depolymerization
Molecular Function	GO:0003779 actin binding GO:0004497 monooxygenase activity GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016709 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen GO:0017016 Ras GTPase binding GO:0017137 Rab GTPase binding GO:0031267 small GTPase binding GO:0048037 cofactor binding GO:0050660 flavin adenine dinucleotide binding GO:0050662 coenzyme binding GO:0051020 GTPase binding GO:0071949 FAD binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	MICAL3
Name	microtubule associated monooxygenase, calponin and LIM domain containing 3
Aliases	KIAA0819; MICAL-3; flavoprotein oxidoreductase MICAL3; molecule interacting with CasL protein 3; protein MIC ......
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MICAL3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MICAL3
Name	microtubule associated monooxygenase, calponin and LIM domain containing 3
Aliases	KIAA0819; MICAL-3; flavoprotein oxidoreductase MICAL3; molecule interacting with CasL protein 3; protein MIC ......
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MICAL3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MICAL3
Name	microtubule associated monooxygenase, calponin and LIM domain containing 3
Aliases	KIAA0819; MICAL-3; flavoprotein oxidoreductase MICAL3; molecule interacting with CasL protein 3; protein MIC ......
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MICAL3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.58	0.081
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.778	0.669
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.434	0.753
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.228	0.422
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.046	0.987
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.46	0.897
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.25	0.57
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.228	0.903
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.296	0.886
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.396	0.73
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.025	0.988
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.198	0.00424

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MICAL3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	18.5	1.4	17.1	0.00519
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	18.5	1.7	16.8	0.0108
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	11.8	-2.3	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	33.3	-20.8	0.538
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	3.7	4.2	0.636
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	7.7	5.9	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	23.1	-23.1	0.223
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	25	-25	0.515

Summary
Symbol	MICAL3
Name	microtubule associated monooxygenase, calponin and LIM domain containing 3
Aliases	KIAA0819; MICAL-3; flavoprotein oxidoreductase MICAL3; molecule interacting with CasL protein 3; protein MIC ......
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MICAL3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MICAL3
Name	microtubule associated monooxygenase, calponin and LIM domain containing 3
Aliases	KIAA0819; MICAL-3; flavoprotein oxidoreductase MICAL3; molecule interacting with CasL protein 3; protein MIC ......
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MICAL3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MICAL3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MICAL3
Name	microtubule associated monooxygenase, calponin and LIM domain containing 3
Aliases	KIAA0819; MICAL-3; flavoprotein oxidoreductase MICAL3; molecule interacting with CasL protein 3; protein MIC ......
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MICAL3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MICAL3
Name	microtubule associated monooxygenase, calponin and LIM domain containing 3
Aliases	KIAA0819; MICAL-3; flavoprotein oxidoreductase MICAL3; molecule interacting with CasL protein 3; protein MIC ......
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MICAL3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MICAL3
Name	microtubule associated monooxygenase, calponin and LIM domain containing 3
Aliases	KIAA0819; MICAL-3; flavoprotein oxidoreductase MICAL3; molecule interacting with CasL protein 3; protein MIC ......
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MICAL3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MICAL3
Name	microtubule associated monooxygenase, calponin and LIM domain containing 3
Aliases	KIAA0819; MICAL-3; flavoprotein oxidoreductase MICAL3; molecule interacting with CasL protein 3; protein MIC ......
Chromosomal Location	22q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MICAL3 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MICAL3